PSMA for detection of prostate cancer recurrence before Phoenix criteria. Is it really always the earlier the better?! Join us EAU YAU Prostate Cancer Working Group for constructive discussion in our comment in European Urology Oncology GUO-AEU sciencedirect.com/science/articl…

External validation of nomograms for predicting lymph node invasion (LNI) in prostate cancer patients with negative PSMA PET-CT. What did we find? The Briganti 2023 nomogram is the most accurate! 📊✅ 🔍 Why does it matter? Extended pelvic lymph node dissection (ePLND) is the

🚨Which is the ROLE of PLND in #ProstateCancer pts with NEGATIVE pre-op PSMA PET? 🧐 Help us find it out by taking part to a 5-min SURVEY! 👉surveymonkey.com/r/K9VWQ83 🤳or use the QR Code 📢Your experience matters! European Association of Urology (EAU) EAU Young Academics Società Italiana di Urologia #UroSoMe

European Association of Urology (EAU) EAU Young Academics Società Italiana di Urologia 🔬 if interested, also join us to be involved in further research!

🔍 PROSTATE CANCER UPDATE: DAROLUTAMIDE. 24 FEBBRAIO 2025. Prof. Ricardi, Prof. Di Maio, Prof. Gontero, Prof. Airoldi. RESPONSABILI SCIENTIFICI Prof. Oderda, Prof. Marra. ✨ Paolo Gontero umberto ricardi Marco Oderda Giancarlo Marra Massimo Di Maio Federico Lavagno, MD

Congrats!! Looking forward to work with you!

🚨 Urologists—your input is needed! 🚨 The YAU Prostate Cancer Group is running a survey on lymph node dissection in #ProstateCancer with negative PSMA PET/CT. Please fill in the survey below! 👇 📝 6-minute survey 📅 Closes 20 March 2025 🔗 surveymonkey.com/r/K9VWQ83 #UroSoMe

Thank you to @AngioDynamics for an excellent 7th Life Symposium in Barcelona last weekend. Great discussions on innovation in focal therapy, including #NanoKnife with insights from @embertonmark Giancarlo Marra and others. Awesome science behind this practice-changing tech ⚡️

Our new SR and MA published in European Urology Oncology evaluates focal therapy for localized PCa using prospective data only. Important for patient counselling. 📊 50 studies, 4,615 patients 📊 12-mo csPCa RFS in intermediate-risk: 79% (95% CI 74–83%) 🔗 doi.org/10.1016/j.euo.…

📰 The UROONCO PCa Article of the Month features a trial comparing standard care vs. supervised exercise with or without psychosexual education to improve sexual function in men with PCa. Read the article with expert commentary by Dr. Giancarlo Marra 👇 prostate.uroonco.uroweb.org/publication/ex…

📹 A #prostatecancer game changer: UROONCO PCa chief editor Dr. Giancarlo Marra (IT) talks to Prof. Fred Saad (CA) on the ARANOTE study: Darolutamide in combination with ADT in patients with mHSPC. 👇 prostate.uroonco.uroweb.org/video/aranote-…

Can treating all visible tumour sites improve outcomes in de novo omPC? Our new Rapid Review in Eur Urol Oncol discusses evidence for "total eradication of tumour" (TET)! 🧠 doi.org/10.1016/j.euo.… Pawel Rajwa steven joniau Tamas Fazekas MD Gert De Meerleer Giancarlo Marra Giorgio Gandaglia Shahrokh F. Shariat

Excited to share our latest paper on ARPI monotherapy in #ProstateCancer Eur Urol Focus EAU YAU Prostate Cancer Working Group Marcin Miszczyk Alexander Giesen Juan Gómez Rivas Axel S. Merseburger steven joniau Giancarlo Marra Nyirády Dr. Péter Giorgio Gandaglia Shahrokh F. Shariat Pawel Rajwa Semmelweis University Urologic Oncology Research MedUni Vienna tinyurl.com/48d4hdtk

A new systematic review & meta-analysis explores the role of androgen receptor pathway inhibitor (ARPI) monotherapy across prostate cancer stages. •⚖️ Similar overall safety to ADT or ARPI+ADT combo •❤️‍🔥 Fewer hot flushes •⚠️ More breast-related side effects (pain &

The incidence of unconventional histologies (UHs) in prostate cancer is increasing significantly, rising from 0.7% in 2010 to 19% in 2023 in radical prostatectomy specimens. However, reporting remains inconsistent, even in leading tertiary centers. 👉 Why does it matter? UHs

📹 At #UROonco25, UROONCO PCa chief editor Dr. Giancarlo Marra spoke to Prof. Prof. Prokar Dasgupta OBE on the usefulness of AI with PCa diagnosis, pathology and surgery, but also the challenges when integrating into clinical practice. Watch here 👇 prostate.uroonco.uroweb.org/video/artifici…

🙏 @uroweb & Prof. Prokar Dasgupta OBE #AI influencing #PCa #diagnosis & #treatment 🗝️ points: 🥉 improvement in 🔬 pathology & 📺 imaging #interpretation 🥈 improvement in 🤖 - #autosuturing a likely upcoming step 🥇 & 🚨 #important : #AI will not replace 🔪 : #surgeon&AI NOT #surgeonvsAI

Ready to elevate your prostate cancer expertise? 🩺 Join the Turin Oncology Prostate cancer (TOP) Masterclass! 🔥 Learn from world experts on the latest diagnosis, treatment, and research. 👉 Join live surgeries, debates, and networking opportunities. 🔗topmasterclass.it

🚨 Relevant work anticipating what we will face 🔜 📈 #Unconventional #Histologies #PCa 👉 One in Five 🧔‍♂️ with #PCa has #UH ⚠️ Under-reported even in tertiary 🏥 TAKE HOME 🥉 #Standardization needed 🥈 #StandardReporting take time but 🥇 #UH #common #finding to deal with

How do outcomes compare when salvage robotic radical prostatectomy (sRARP) follows focal therapy vs. radiation therapy? 📌 Key Findings: •Patients post-RT had more aggressive tumors and worse metastasis-free and overall survival, but only before adjustment. •sRARP after FT is